Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of British Columbia
$27,000.00
Investigating and restoring Parvalbumin-expressing interneuron development in Huntington’s Disease
FY 2025-26
Summary
Huntington’s disease (HD) is a genetic neurodegenerative condition that appears in adulthood, affecting movement, mood, and cognition. However, new evidence suggests that brain circuit irregularities appear well before the appearance of symptoms, during brain development. Our preliminary findings are in-line with previous work and have revealed a particularly vulnerable part of brain wiring involving parvalbumin interneurons (PV-INs). These specialized cells play a role in maintaining a balance of excitatory and inhibitory signals, keeping brain circuits stable. Our data identify a reduction in PV-INs at early stages of the disease, suggesting a deficit in this key cell type. Interestingly, the maturation of PV-INs is activity-dependent, meaning that they must remain active to develop critical characteristics to their mature function. Recent findings have shown that this maturation pathway is regulated by proteins that are known from past work to be impacted in HD; which could explain why we observe less PV-INs at early stages of HD. Our experiments will begin by building on our preliminary findings in a mouse model of HD to identify when the earliest changes in PV-IN development occur, and how characteristics of these cells are altered at each stage. Once we can establish the timeline for PV-IN maturation in HD, and how it differs from healthy mice, we will focus on directly facilitating the activity-dependent maturation pathway to rescue the deficits. We will do so using drugs to increase PV-IN activity during a critical time window early in development, followed by a re-assessment of the maturation timeline previously established. If successful, our work would validate this cell type as a promising new therapeutic target and open a new path for early HD treatments.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573254
Name
Rivera Joel
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating and restoring Parvalbumin-expressing interneuron development in Huntington’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cortex; Development; Drug; Huntington’S Disease; Interneuron; Intervention; Maturation; Neurodevelopment; Parvalbumin
Abstract
Huntington’s disease (HD) is a genetic neurodegenerative condition that appears in adulthood, affecting movement, mood, and cognition. However, new evidence suggests that brain circuit irregularities appear well before the appearance of symptoms, during brain development. Our preliminary findings are in-line with previous work and have revealed a particularly vulnerable part of brain wiring involving parvalbumin interneurons (PV-INs). These specialized cells play a role in maintaining a balance of excitatory and inhibitory signals, keeping brain circuits stable. Our data identify a reduction in PV-INs at early stages of the disease, suggesting a deficit in this key cell type. Interestingly, the maturation of PV-INs is activity-dependent, meaning that they must remain active to develop critical characteristics to their mature function. Recent findings have shown that this maturation pathway is regulated by proteins that are known from past work to be impacted in HD; which could explain why we observe less PV-INs at early stages of HD. Our experiments will begin by building on our preliminary findings in a mouse model of HD to identify when the earliest changes in PV-IN development occur, and how characteristics of these cells are altered at each stage. Once we can establish the timeline for PV-IN maturation in HD, and how it differs from healthy mice, we will focus on directly facilitating the activity-dependent maturation pathway to rescue the deficits. We will do so using drugs to increase PV-IN activity during a critical time window early in development, followed by a re-assessment of the maturation timeline previously established. If successful, our work would validate this cell type as a promising new therapeutic target and open a new path for early HD treatments.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rivera, Joel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~